Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
27 oct. 2021 17h42 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month
20 oct. 2021 08h00 HE
|
Supernus Pharmaceuticals, Inc.
Peete and her daughter Ryan join forces to amplify the conversation around Attention-deficit/Hyperactivity disorder (ADHD) and neurodiversityNearly one-in-ten – or 6.1 million children and adolescents...
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
11 oct. 2021 06h30 HE
|
Supernus Pharmaceuticals, Inc.
Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to...
Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA
02 sept. 2021 18h45 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in Upcoming September Investor Conferences
02 sept. 2021 09h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Second Quarter 2021 Financial Results
04 août 2021 16h09 HE
|
Supernus Pharmaceuticals, Inc.
Second quarter 2021 total revenues of $141.3 million, a 12% increase compared to 2020Qelbree™ launched in the U.S. for pediatric ADHD at the end of May 2021Qelbree sNDA for adult ADHD submitted to the...
Supernus to Host Second Quarter 2021 Financial Results Conference Call
22 juil. 2021 16h37 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., July 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at Jefferies Virtual Healthcare Conference
25 mai 2021 08h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age
24 mai 2021 08h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2021 Financial Results
05 mai 2021 16h01 HE
|
Supernus Pharmaceuticals, Inc.
First quarter 2021 total revenues of $130.9 million, a 38% increase compared to 2020Qelbree™ approved by FDA for pediatric ADHD and on track for a U.S. launch in Q2 2021Qelbree sNDA submission for...